I C Barıs1, S Hacıoglu2, N S Turk3, G O Cetın4, S Zencır1,5, G Bagcı4, V Caner6. 1. Department of Medical Biology, School of Medicine, Pamukkale University, Denizli, Turkey. 2. Department of Hematology, School of Medicine, Pamukkale University, Denizli, Turkey. 3. Department of Medical Pathology, School of Medicine, Pamukkale University, Denizli, Turkey. 4. Department of Medical Genetics, School of Medicine, Pamukkale University, Denizli, Turkey. 5. Department of Molecular Biology, University of Geneva, 1211, Geneva 4, Switzerland. 6. Department of Medical Genetics, School of Medicine, Pamukkale University, Denizli, Turkey. vcaner@pau.edu.tr.
Abstract
AIMS: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. This study was designed to compare epigenetic alterations observed in Enhancer of Zeste Homolog 2 (EZH2)-target genes between plasma-derived exosomes and primary tumors in DLBCL patients. MAIN METHODS: Exosomes were isolated from plasma of 21 DLBCL patients and 21 controls. We analyzed the methylation status of the target genes using methylation-specific PCR. We also examined whether the exosomes and the tumor samples contained transcripts of the target genes. KEY FINDINGS: We found that CDKN2A and CDKN2B were methylated in both plasma exosomes and primary tumor tissue samples. None of the transcripts were found in the exosomes except CDKN1B which was expressed in 8 (38%) of the exosome samples. SIGNIFICANCE: This study showed that plasma exosomes might preferably package certain target molecules from primary tumors and the exosomes containing dual methylated DNAs of CDKN2A and CDKN2B, or CDKN1B transcript may contribute to DLBCL pathogenesis.
AIMS: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. This study was designed to compare epigenetic alterations observed in Enhancer of Zeste Homolog 2 (EZH2)-target genes between plasma-derived exosomes and primary tumors in DLBCL patients. MAIN METHODS: Exosomes were isolated from plasma of 21 DLBCL patients and 21 controls. We analyzed the methylation status of the target genes using methylation-specific PCR. We also examined whether the exosomes and the tumor samples contained transcripts of the target genes. KEY FINDINGS: We found that CDKN2A and CDKN2B were methylated in both plasma exosomes and primary tumor tissue samples. None of the transcripts were found in the exosomes except CDKN1B which was expressed in 8 (38%) of the exosome samples. SIGNIFICANCE: This study showed that plasma exosomes might preferably package certain target molecules from primary tumors and the exosomes containing dual methylated DNAs of CDKN2A and CDKN2B, or CDKN1B transcript may contribute to DLBCL pathogenesis.
Entities:
Keywords:
Diffuse large B-cell lymphoma; EZH2-target genes; Epigenetics; Exosome
Authors: Irina Velichutina; Rita Shaknovich; Huimin Geng; Nathalie A Johnson; Randy D Gascoyne; Ari M Melnick; Olivier Elemento Journal: Blood Date: 2010-08-24 Impact factor: 22.113
Authors: Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino Journal: Int J Cancer Date: 2011-03-01 Impact factor: 7.396
Authors: Kenneth W Witwer; Edit I Buzás; Lynne T Bemis; Adriana Bora; Cecilia Lässer; Jan Lötvall; Esther N Nolte-'t Hoen; Melissa G Piper; Sarada Sivaraman; Johan Skog; Clotilde Théry; Marca H Wauben; Fred Hochberg Journal: J Extracell Vesicles Date: 2013-05-27
Authors: Jan Lötvall; Andrew F Hill; Fred Hochberg; Edit I Buzás; Dolores Di Vizio; Christopher Gardiner; Yong Song Gho; Igor V Kurochkin; Suresh Mathivanan; Peter Quesenberry; Susmita Sahoo; Hidetoshi Tahara; Marca H Wauben; Kenneth W Witwer; Clotilde Théry Journal: J Extracell Vesicles Date: 2014-12-22